• 1. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 2. Distinctive size effects of Pt nanoparticles immobilized on Fe3O4@PPy used as an efficient recyclable catalyst for benzylic alcohol aerobic oxidation and hydrogenation reduction of nitroaromatics
  Yu Long,Bing Yuan,Jianrui Niu,Xin Tong,Jiantai Ma New J. Chem., 2015,39, 1179-1185
• 3. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

Recent Advances in the Application of (3-Bromo-2-fluoro-4-methylphenyl)boronic acid (CAS: 2377608-04-1) in Chemical Biology and Pharmaceutical Research

The compound (3-Bromo-2-fluoro-4-methylphenyl)boronic acid (CAS: 2377608-04-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in medicinal chemistry, particularly in the development of novel therapeutic agents and diagnostic tools. This boronic acid derivative serves as a crucial intermediate in Suzuki-Miyaura cross-coupling reactions, a widely utilized method for constructing biaryl structures in drug discovery. Recent studies have highlighted its role in the synthesis of potent kinase inhibitors and other bioactive molecules targeting various diseases, including cancer and infectious diseases.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers demonstrated the efficacy of (3-Bromo-2-fluoro-4-methylphenyl)boronic acid as a key building block for the synthesis of selective Bruton's tyrosine kinase (BTK) inhibitors. These inhibitors showed promising results in preclinical models of B-cell malignancies, with enhanced pharmacokinetic properties attributed to the boronic acid moiety. The study underscores the compound's potential in addressing drug resistance mechanisms observed in current BTK inhibitor therapies.

Further investigations have explored the application of this boronic acid derivative in the development of positron emission tomography (PET) tracers. A recent Nature Communications article reported its incorporation into fluorine-18 labeled probes for imaging amyloid-beta plaques in Alzheimer's disease. The unique electronic properties imparted by the bromo and fluoro substituents on the phenyl ring were found to significantly improve blood-brain barrier penetration and target binding affinity, making it a valuable scaffold for neuroimaging applications.

From a synthetic chemistry perspective, advances in the preparation and handling of (3-Bromo-2-fluoro-4-methylphenyl)boronic acid have been reported. A 2024 ACS Catalysis publication detailed an improved synthetic route that enhances yield and purity while reducing environmental impact through greener solvent systems. These methodological improvements are particularly important given the increasing demand for this compound in high-throughput screening and combinatorial chemistry approaches.

The safety profile and physicochemical properties of (3-Bromo-2-fluoro-4-methylphenyl)boronic acid have also been systematically evaluated in recent toxicological studies. Research published in Chemical Research in Toxicology demonstrated favorable stability and manageable toxicity levels, supporting its continued use in pharmaceutical development. However, researchers caution that proper handling protocols should be maintained due to potential boronic acid-related hazards.

Looking forward, the unique structural features of this compound continue to inspire novel applications. Current research directions include its incorporation into covalent inhibitors targeting SARS-CoV-2 proteases and its use in developing boron neutron capture therapy (BNCT) agents. The compound's versatility and the growing understanding of boronic acid chemistry suggest it will remain an important tool in medicinal chemistry for years to come.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)